AbbVie Inc (ABBV)vsAkso Health Group ADR (AHG)
ABBV
AbbVie Inc
$227.23
+1.32%
HEALTHCARE · Cap: $380.57B
AHG
Akso Health Group ADR
$1.34
-8.22%
HEALTHCARE · Cap: $1.70B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 423143% more annual revenue ($62.82B vs $14.84M). ABBV leads profitability with a 5.8% profit margin vs 0.0%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
AHG
Avoid16
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-55.6%
Fair Value
$146.00
Current Price
$227.23
$81.23 premium
Margin of Safety
+18.0%
Fair Value
$1.72
Current Price
$1.34
$0.38 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 3.6B in free cash flow
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
0.9% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.59 suggests the stock is reasonably priced for its growth.
Bull Case : AHG
The strongest argument for AHG centers on Debt/Equity, Altman Z-Score.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 105.1x leaves little room for execution misses.
Bear Case : AHG
The primary concerns for AHG are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
ABBV carries more volatility with a beta of 0.30 — expect wider price swings.
ABBV is growing revenue faster at 12.4% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (63/100 vs 16/100) and 12.4% revenue growth. AHG offers better value entry with a 18.0% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Akso Health Group ADR
HEALTHCARE · MEDICAL DISTRIBUTION · China
Akso Health Group ADR is a leading entity in the healthcare sector, focused on delivering innovative medical solutions and comprehensive patient care services. The company utilizes advanced health technologies to exploit burgeoning opportunities in telehealth and personalized medicine, supported by a strong emphasis on research and development. With a solid business model and a highly proficient workforce, Akso Health Group represents a compelling investment opportunity for institutional investors looking to capitalize on the dynamic changes within the healthcare industry.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?